论文部分内容阅读
Continuous diagnostic variables are often split at a cutoff value for diagnosis of diseased and normal status.
The most concordant cutoff point from an ROC curve for
【摘 要】
：
Continuous diagnostic variables are often split at a cutoff value for diagnosis of diseased and normal status.
【机 构】
：
Department of Biostatistics,SJTU Medical School,SJTU,Shanghai,200025,China;Department of Biomedical
【出 处】
：
上海交通大学
【发表日期】
：
2016年4期
其他文献
A Bayesian logistic regression model with cohort size adaptation based on posterior probabilities in
The primary objective of cancer phase Ⅰ studies is to determine the maximum tolerated dose(MTD).
In this talk,we will talk about embedding a non-parametric multiple change-point problem into a parametric framework.
In the early phase development of molecularly targeted agents(MTAs),a commonly encountered situation is that the MTA is expected to be more effective for a certain biomarker subgroup,say marker-positi
In this paper,we consider functional partial linear models proposed by Lian(2011)when the response variables are missing at random.
In pivotal Phase 3 trials where adverse events have been identified in advance,regulatory requirements often call for development programs to adequately demonstrate an acceptable drug safety profile.
Business analytics refers to data-driven decision making in business.Nonparametric methods are playing an increasing role in business analytics,fueled by increasing data complexity and dimensionality.
Penalized empirical likelihood inference for sparse additive hazards regression with a divergent num
High-dimensional sparse modelling with censored survival data is of great practical importance,as exemplified by applications in high-throughput genomic data analysis.
Let XH(t)(t)= {XH(t)(t),t ∈ RN+} be multifractional stable sheets with Hurst function H(t),where H(t)=(H1(t),...,HN(t))is a function in t ∈ RN+with values in(0,1)N.
One of the main purposes of a phase dose-finding trial in oncology is to identify a tolerable dose with an indication of therapeutic benefit to administer to subjects in subsequent phase Ⅱ and Ⅲ trial
It is of fundamental importance to infer how the conditional mean of the response varies with the predictors in high dimensional data analysis.